AG0301-COVID19 / Takara, AnGes MG, Osaka University Graduate School of Medicine, Fresh Tracks Therap - LARVOL DELTA

Study of COVID-19 DNA Vaccine (AG0301-COVID19) (clinicaltrials.gov) - P1/2; N=30; Completed; Sponsor: AnGes, Inc.; Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

AnGes and Brickell Biotech Announce a Collaboration Agreement for the Development of a Novel DNA Vaccine Candidate for COVID-19 in the U.S. (GlobeNewswire) - "AnGes, Inc. ('AnGes'), announced today a collaboration agreement with Brickell Biotech, Inc....through which Brickell has the right to develop AnGes’ proprietary investigational adjuvanted plasmid DNA vaccine intended to prevent SARS-CoV-2 (COVID-19) in the U.S., South America and certain emerging markets. AnGes is currently conducting Phase 1/2 clinical studies with its vaccine candidate in Japan, with data readouts expected through the first quarter of 2021....AnGes will continue to lead the development of its vaccine candidate in Japan and Brickell will provide information and know-how..."

Licensing / partnership • P1/2 data • Infectious Disease • Novel Coronavirus Disease

Study of COVID-19 DNA Vaccine (AG0301-COVID19) (clinicaltrials.gov) - P1/2; N=30; Active, not recruiting; Sponsor: AnGes, Inc.; Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

A Phase I / II Study of COVID-19 DNA Vaccine (AG0301-COVID19) (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: AnGes, Inc.

Clinical • New P1/2 trial • Infectious Disease • Novel Coronavirus Disease